Greenrose Holding Co Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Falcon John, was filed 23 Feb 2022.
Greenrose Holding Co Inc.: what insiders have been doing
This page follows insider dealings at Greenrose Holding Co Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Greenrose Holding Co Inc. in twelve months, the latest record being from 23 February 2022.
Looking back to 2022, when coverage begins, insiders filed 2 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: UCB. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
- 22,480 shares0Greenrose Holding Company Inc Common StockSEC:0001213900-22-008988:0
- 51,220 shares0Greenrose Holding Company Inc Common StockSEC:0001213900-22-008951:0Canonical exit: 19 May 2022 (T+90)
- 685,289 sharesGreenrose Holding Company Inc Common StockSEC:0001213900-22-005733:0Canonical exit: 4 May 2022 (T+90)
3 of 3 declarations
About Greenrose Holding Co Inc.
The Greenrose Holding Company Inc. is a U.S.-based company historically exposed to the medical cannabis and cannabinoid-products market. The most recent market profile data reviewed describes the company as founded in 2014 and headquartered in Amityville, New York, United States. Its operating footprint was built through subsidiaries involved in cultivating, processing, packaging, and selling medical cannabis and derivative products. In other words, Greenrose was structured around a vertically integrated cannabis model, aiming to control more of the value chain from production to finished products and downstream commercialization. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/))
From an equity analyst perspective, Greenrose has operated in a niche industry defined by heavy regulation, high execution risk, and a fragmented competitive landscape. In this type of business, competitive positioning typically depends on licensing, compliance, cultivation efficiency, product quality, and the ability to maintain stable retail or wholesale channels. Greenrose’s historical niche was medical cannabis rather than a diversified pharmaceutical platform, so its risk profile has been materially tied to the regulatory environment for cannabis in the United States, operating leverage in cultivation and processing, and access to capital. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/))
Read moreShow less
A critical recent development is that The Greenrose Holding Company Inc. filed a voluntary petition for liquidation under Chapter 7 on June 18, 2024, in the U.S. Bankruptcy Court for the Eastern District of New York. That filing changes the investment case substantially. Instead of a normal operating-growth story, the company should now be viewed as a distressed or liquidation-stage situation, with limited forward visibility on ordinary business performance. For investors tracking SEC Form 4 insider activity, that context matters: insider transactions should be interpreted against the backdrop of bankruptcy proceedings and a much weaker capital-structure profile. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/))
On the market side, the latest profile reviewed shows GNRSQ quoted on the OTC Markets rather than on the NYSE or NASDAQ. So while the company is a U.S. issuer, it is not currently presented as a mainstream large-cap or mid-cap exchange-listed name. Its geographical footprint has remained U.S.-centric, with Amityville, New York listed as the headquarters and no meaningful international operating presence indicated in the sources reviewed. For French-speaking investors in France, Belgium, or Switzerland, the key takeaway is that Greenrose is best understood as a highly speculative U.S. cannabis-related situation with significant legal and financial overhangs, rather than as a conventional listed consumer-health or pharmaceutical business. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/))
